Becky Pennington

Population Health, School of Medicine and Population Health

Research Fellow

b.pennington@sheffield.ac.uk
+44 114 222 0745

Regent Court (ScHARR)

Full contact details

Becky Pennington
Population Health, School of Medicine and Population Health
Regent Court (ScHARR)
30 Regent Street
Sheffield
S1 4DA

Profile

I am undertaking a National Institute for Health Research (NIHR) doctoral research fellowship studying carer health-related quality of life and its inclusion in economic evaluations. My fellowship focusses on analysing change in carer health-related quality of life using longitudinal data and exploring how this can be incorporated into cost-effectiveness models. The project builds on my previous research as part of the Decision Support Unit for the National Institute for Health and Care Excellence (NICE) reviewing the inclusion of carer health-related quality of life in NICE appraisals (Pennington, 2020).

I joined ScHARR in 2017 as a member of the Decision Support Unit, where I worked as a health economic modeller on appraisal-specific and methodological research projects. Prior to this I worked as a Technical Adviser at NICE in public health and social care guidelines, and as a Principal Health Economist in consultancy developing economic models and submissions for health technology assessment. Whilst working in consultancy I completed my MSc in Health Economics and Decision Modelling at The University of Sheffield. I have a BSc in Mathematics from The University of Sheffield.

I am a member of NICE’s Technology Appraisal Committee A.

Publications

Show: Featured publications All publications

Featured publications

This person does not have any publications available.

All publications

Journal articles

Henry E, Al-Janabi H, Brouwer W, Cullinan J, Engel L, Griffin S, Hulme C, Kingkaew P, Lloyd A, Payakachat N , Pennington B et al (2023) Recommendations for Emerging Good Practice and Future Research in Relation to Family and Caregiver Health Spillovers in Health Economic Evaluations: A Report of the SHEER Task Force. PharmacoEconomics, 1-20.
Mott DJ, Schirrmacher H, Al-Janabi H, Guest S, Pennington B, Scheuer N, Shah KK & Skedgel C (2023) Modelling spillover effects on informal carers: the carer QALY trap. PharmacoEconomics, 41(12), 1557-1561. View this article in WRRO
Scope A, Bhadhuri A & Pennington B (2022) Systematic Review of Cost-Utility Analyses That Have Included Carer and Family Member Health-Related Quality of Life. Value in Health, 25(9), 1644-1653.
Love-Koh J, Pennington B, Owen L, Taylor M & Griffin S (2021) Corrigendum to “How health inequalities accumulate and combine to affect treatment value: A distributional cost-effectiveness analysis of smoking cessation interventions” [Soc. Sci. Med. 265 (2020) 113339]. Social Science & Medicine, 280, 114060-114060.
Pennington R, Alshreef A, Flight L, Metry A, Poku E, Hykin P, Sivaprasad S, Prevost AT, Vasconcelos JC, Murphy C , Kelly J et al (2021) Cost effectiveness of ranibizumab vs aflibercept vs bevacizumab for the treatment of macular oedema due to central retinal vein occlusion: the LEAVO study. PharmacoEconomics. View this article in WRRO
Love-Koh J, Pennington B, Owen L, Taylor M & Griffin S (2020) How health inequalities accumulate and combine to affect treatment value: A distributional cost-effectiveness analysis of smoking cessation interventions. Social Science & Medicine, 265.
Pennington BM (2020) Inclusion of carer health-related quality of life in national institute for health and care excellence appraisals. Value in Health, 23(10), 1349-1357.
Pennington BM, Hernández-Alava M, Hykin P, Sivaprasad S, Flight L, Alshreef A & Brazier J (2020) Mapping from visual acuity to EQ-5D, EQ-5D with vision bolt-on, and VFQ-UI in patients with macular edema in the LEAVO trial. Value in Health. View this article in WRRO
Hill J, Pennington R, Wailoo A, Wong R & Rowen D (2020) A review of the methods used to generate utility values in NICE technology assessments for children and adolescents. Value in Health. View this article in WRRO
Griffiths PD, Bradburn M, Campbell MJ, Cooper CL, Embleton N, Graham R, Hart AR, Jarvis D, Kilby MD, Lie M , Mason G et al (2019) MRI in the diagnosis of fetal developmental brain abnormalities : the MERIDIAN diagnostic accuracy study. Health Technology Assessment, 23(49), 1-144. View this article in WRRO
Griffin S, Love-Koh J, Pennington B & Owen L (2019) Evaluation of Intervention Impact on Health Inequality for Resource Allocation.. Medical Decision Making. View this article in WRRO
Pennington B, Ren S, Barton S, Bacelar M & Edwards SJ (2018) Dinutuximab Beta for Treating Neuroblastoma: An Evidence Review Group and Decision Support Unit Perspective of a NICE Single Technology Appraisal. PharmacoEconomics. View this article in WRRO
Pennington B, Hernandez-Alava M, Pudney S & Wailoo A (2018) The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals. PharmacoEconomics. View this article in WRRO
Pennington RM, Collins B, Leigh S, Martin AP, Owen L, Fischer A, Sumnall H & Bates G (2018) The cost-effectiveness of seven behavioural interventions to prevent drug misuse in vulnerable populations. International Journal of Drug Policy, 57, 42-50. View this article in WRRO
Pennington B, Filby A, Owen L & Taylor M (2018) Smoking Cessation: A Comparison of Two Model Structures. PharmacoEconomics, 36(9), 1101-1112. View this article in WRRO
Pennington B, Marriott E-R, Lichtlen P, Akbar A & Hatswell AJ (2018) The Cost Effectiveness of Lubiprostone in Chronic Idiopathic Constipation. PharmacoEconomics - Open, 2(3), 241-253.
Owen L, Pennington RM, Fischer A & Jeong K (2017) The cost-effectiveness of public health interventions examined by NICE from 2011 to 2016. Journal of Public Health. View this article in WRRO
Sadler S, Tosh J, Pennington R, Rawdin A, Squires H, Romero C, Fischer A & Chilcott J (2017) A cost-effectiveness analysis of condom distribution programmes for the prevention of sexually transmitted infections in England.. Journal of Epidemiology and Community Health, 71, 897-904. View this article in WRRO
Pennington B, Akehurst R, Wasan H, Sangro B, Kennedy AS, Sennfält K & Bester L (2015) Cost-effectiveness of selective internal radiation therapy using yttrium-90 resin microspheres in treating patients with inoperable colorectal liver metastases in the UK. Journal of Medical Economics, 18(10), 797-804.
Hatswell AJ, Pennington B, Pericleous L, Rowen D, Lebmeier M & Lee D (2014) Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death. Health and Quality of Life Outcomes, 12. View this article in WRRO
Pennington B & Davis S (2014) Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results. Value in Health, 17(8), 762-771. View this article in WRRO
Pennington B, Marriott E, Sophia H, Lichtlen P & Hatswell AJ (2014) Lubiprostone In Chronic Idiopathic Constipation: A Cost-Effectiveness Analysis. Value in Health, 17(7), A366-A366.
Hatswell AJ, Griffiths A, Lichtlen P, Losch-Beridon T & Pennington B (2014) Which Metric To Choose For Indirect Comparison Of Treatments When Multiple Comparisons Are Feasible: Lubiprostone Verse Prucalopride In Chronic Constipation. Value in Health, 17(7), A371-A371.
Brereton N, Pennington B, Ekelund M & Akehurst R (2014) A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model. Journal of Medical Economics, 17(9), 677-684.
Batty AJ, Hansen RN, Bloudek LM, Varon SF, Hayward EJ, Pennington BW, Lipton RB & Sullivan SD (2013) The cost-effectiveness of onabotulinumtoxinA for the prophylaxis of headache in adults with chronic migraine in the UK. Journal of Medical Economics, 16(7), 877-887.
Pennington B & Al-Janabi H () Modelling Informal Carers’ Health-Related Quality of Life: Challenges for Economic Evaluation. Applied Health Economics and Health Policy.
Pennington B, Eaton J, Hatswell AJ & Taylor H () Carers’ Health-Related Quality of Life in Global Health Technology Assessment: Guidance, Case Studies and Recommendations. PharmacoEconomics.
Pennington B, Alshreef A, Flight L, Metry A, Poku E, Hykin P, Sivaprasad S, Prevost AT, Vasconcelos JC, Murphy C , Kelly J et al () Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study. PharmacoEconomics.
Hykin P, Prevost AT, Sivaprasad S, Vasconcelos JC, Murphy C, Kelly J, Ramu J, Alshreef A, Flight L, Pennington R , Hounsome B et al () Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT. Health Technology Assessment.
Rowen D, Keetharuth D, Poku E, Wong R, Pennington R & Wailoo A () A review of the psychometric performance of selected child and adolescent preference-based measures used to produce utilities for child and adolescent health. Value in Health. View this article in WRRO
Shields GE, Pennington B, Bullement A, Wright S & Elvidge J () Out of Date or Best Before? A Commentary on the Relevance of Economic Evaluations Over Time. PharmacoEconomics.

Conference proceedings papers

Flight L, Alshreef A, Hykin PG, Sivaprasad S, Pennington B, Kelly J, Murphy CL & Brazier JE (2019) Intravitreal therapy with Ranibizumab vs Aflibercept vs Bevacizumab for macular oedema due to central retinal vein occlusion : a within trial cost-utility analysis. Value in Health, Vol. 22(Suppl 3) (pp S664-S664). Copenhagen, Denmark, 2 November 2019 - 6 November 2019. View this article in WRRO
Pennington B, Alshreef A, Flight L, Hykin P, Sivaprasad S, Brazier JE & Hernández M (2019) PSS25 Mapping from visual acuity to utility in patients with macular oedema due to central retinal vein occlusion using data from the LEAVO trial. Value in Health, Vol. 22(Suppl. 3) (pp S891-S891). Copenhagen, Denmark, 2 November 2019 - 6 November 2019. View this article in WRRO

Posters

Pennington R Technical Support Document: Identifying and reviewing evidence to inform the conceptualisation and population of cost-effectiveness models: One page summary.
Pennington R Technical Support Document: Survival analysis: One page summary.
Pennington R Technical Support Document: Cost-effectiveness modelling using patient-level simulation: One page summary.

Datasets

Pennington R, Hernandez M, Hykin P, Sivaprasad S, Flight L, Alshreef A & Brazier J Utility calculator for visual acuity.